Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) BCL9 Antibodies:
anti-Human BCL9 Antibodies:
anti-Rat (Rattus) BCL9 Antibodies:
Go to our pre-filtered search.
Both XBcl9 and XPygo2 are required to induce supernumerary axis and dorsal gene activation in Xenopus embryos.
Transcriptional cofactors Bcl9, Bcl9l (show BCL9L Antibodies) and Pygo1 (show PYGO1 Antibodies)/2 act independently of beta-catenin (show CTNNB1 Antibodies) to ensure proper enamel formation.
ARX positively regulates Wnt (show WNT2 Antibodies)/ beta-catenin (show CTNNB1 Antibodies) signaling and the C-terminal domain of ARX interacts with the armadillo (show PKP1 Antibodies) repeats in beta-catenin (show CTNNB1 Antibodies) to promote Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling. In addition, we found BCL9 and P300 (show NOTCH1 Antibodies) also interact with ARX to modulate Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling.
Study demonstrates that the Golgi resident protein GM130 (show GOLGA2 Antibodies) activates the spindle assembly factor TPX2 (show DAZL Antibodies) to nucleate microtubules around the Golgi and further captures them to couple mitotic membranes to the spindle.
Pax6 (show PAX6 Antibodies), the master regulator of eye development, directly activates Bcl9/9l transcription.
These results suggest a critical role of BCL9/9-2 in the Wnt (show WNT2 Antibodies)-mediated regulation of adult, as opposed to embryonic, myogenic progenitors.
MEF2D (show MEF2D Antibodies)-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9 (show HDAC9 Antibodies).
it was demonstrated that miR218 modulated a novel molecular target and the present study provided novel insights into potential mechanisms of RCC (show XRCC1 Antibodies) oncogenesis.
findings indicate that BCL9 most likely does not harbor a common genetic variant that can increase the risk for schizophrenia in the Japanese population
BCL9/9L-beta-catenin (show CTNNB1 Antibodies) Signaling is Associated With Poor Outcome in Colorectal Cancer
BCL9 is a molecular driver of DCIS invasive progression.
PCDH10 (show PCDH10 Antibodies) antagonized MM cell proliferation via the downregulation of Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies)/BCL-9 signaling, whereas PCDH10 (show PCDH10 Antibodies) repressed the expression of AKT (show AKT1 Antibodies) to promote the expression of GSK3beta (show GSK3b Antibodies) and then to restrain the activation of beta-catenin (show CTNNB1 Antibodies)
By beta-catenin's association with LEF1 (show LEF1 Antibodies) and BCL9-2/B9L (show BCL9L Antibodies).
MiR (show MLXIP Antibodies)-30-5p downregulation occurs as a result of interaction between multiple myeloma cells and bone marrow stromal cells, which in turn enhances expression of BCL9.
we detected five SNPs in the first two genes/loci - BCL9 and C9orf5 - strongly associated with negative symptoms of schizophrenia
Inhibition of the BCL9-beta-catenin (show CTNNB1 Antibodies) interaction and selectively suppresses oncogenic Wnt (show WNT2 Antibodies) transcription.
BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.
B-cell CLL/lymphoma 9
, B-cell lymphoma 9
, B-cell CLL/lymphoma 9 protein-like
, b-cell CLL/lymphoma 9 protein-like
, B-cell CLL/lymphoma 9 protein
, B-cell lymphoma 9 protein
, nuclear co-factor of beta-catenin signalling
, protein legless homolog